Jinan Transon CNC Equipment Co., Ltd.
S I N C E 2 0 1 0
Latest products
Using a new type of microfluidic technology to detect the cancer cells in the blood
by：Transon
2021-01-08
Research team is currently trying different methods to improve cancer blood test * * * *.
From tracking cancer RNA traces, to detect almost all cancer types has unique DNA nanostructures, we are standing on an exciting technology.
the current prospective study, the detection of circulating tumor cells in the blood samples ( CTC) , perhaps is a kind of efficient method. These cells will the blood of patients with primary tumor off to the ( Stock few) , but scientists faces a big challenge, is to produce a device that can detect the single-celled.
the prototype device can detect tiny blood samples of more than 90% of tumor cells, Figure since: Ian Papautsky) Corresponding author Ian Papautsky explained: & quot; In a typical 7. 5 ml of blood in vitro, 35-4 billion cells, and may contain cancer 10 or so, this is a search for a needle in a haystack & quot; 。 The good news is that the new diagnostic equipment, can use microfluidics technology, the cancer cells from other cells in any given blood samples. With other lock biomarkers for fluid device ( Affinity separation) Is different, the new device based on the theory of inertia migration, able to filter out the CTC is quite unique.
Papautsky said: & quot; Using size differences to cell types in the separation of fluid, much easier than the affinity separation. The latter using & lsquo; Viscous & rsquo; TAB to capture the right cell type, the follow-up still need to work on advanced purification & quot; 。
above illustrates the separation of the tumor cells from the blood samples ( From: Ian Papautsky) Early test results show that the performance of the new device is very bright eye, successfully from 50 CTC with 5 ml blood samples, captured 93% of the cancer cells. Researchers at eight on blood samples from cancer patients were tested, the results found & ndash; — Even if add 10 CTCS in 5 ml sample cells, the detection rate is as high as 83%.
it is understood that in addition to two of the samples, the device can be detected with CTC. As for did not check out the reason, the researchers speculated that should be the amount of blood sample is too small. It should be pointed out that, although only in the first test in view of the CTC non-small cell lung cancer, but researchers think that the system is also applicable to other types of cancer detection, such as breast cancer and liver cancer. As long as CTC is greater than the blood cells, the device can be widely used. But if the minimum quantity of rare CTC less than a lot of blood, the device is still missing it.
in order to promote accuracy, the researchers next plan, is in a wider range of tests to further verify the effect of the device, also can add additional biomarkers ( Such as cancer DNA tests) 。
for details of the research, has published recently in the micro system and the nano engineering ( 微系统与 纳米工程) The journal. If there is any infringement, please contact the site administrator to deal with!
the current prospective study, the detection of circulating tumor cells in the blood samples ( CTC) , perhaps is a kind of efficient method. These cells will the blood of patients with primary tumor off to the ( Stock few) , but scientists faces a big challenge, is to produce a device that can detect the single-celled.
the prototype device can detect tiny blood samples of more than 90% of tumor cells, Figure since: Ian Papautsky) Corresponding author Ian Papautsky explained: & quot; In a typical 7. 5 ml of blood in vitro, 35-4 billion cells, and may contain cancer 10 or so, this is a search for a needle in a haystack & quot; 。 The good news is that the new diagnostic equipment, can use microfluidics technology, the cancer cells from other cells in any given blood samples. With other lock biomarkers for fluid device ( Affinity separation) Is different, the new device based on the theory of inertia migration, able to filter out the CTC is quite unique.
Papautsky said: & quot; Using size differences to cell types in the separation of fluid, much easier than the affinity separation. The latter using & lsquo; Viscous & rsquo; TAB to capture the right cell type, the follow-up still need to work on advanced purification & quot; 。
above illustrates the separation of the tumor cells from the blood samples ( From: Ian Papautsky) Early test results show that the performance of the new device is very bright eye, successfully from 50 CTC with 5 ml blood samples, captured 93% of the cancer cells. Researchers at eight on blood samples from cancer patients were tested, the results found & ndash; — Even if add 10 CTCS in 5 ml sample cells, the detection rate is as high as 83%.
it is understood that in addition to two of the samples, the device can be detected with CTC. As for did not check out the reason, the researchers speculated that should be the amount of blood sample is too small. It should be pointed out that, although only in the first test in view of the CTC non-small cell lung cancer, but researchers think that the system is also applicable to other types of cancer detection, such as breast cancer and liver cancer. As long as CTC is greater than the blood cells, the device can be widely used. But if the minimum quantity of rare CTC less than a lot of blood, the device is still missing it.
in order to promote accuracy, the researchers next plan, is in a wider range of tests to further verify the effect of the device, also can add additional biomarkers ( Such as cancer DNA tests) 。
for details of the research, has published recently in the micro system and the nano engineering ( 微系统与 纳米工程) The journal. If there is any infringement, please contact the site administrator to deal with!
Custom message
